SFX by Ex Libris Inc.

Users interested in this article also expressed an interest in the following:
description	1.	Wang, H. "Adoptive Antitumor Immunotherapy In Vitro and In Vivo Using Genetically Activated erbB2-specific T Cells." Journal of immunotherapy Publish Ahead of Print.7 (2014): 351-9.
description	2.	Kandalaft, Mythili E. "A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer." Journal of translational medicine 10.1 (2012): 157-102.
description	3.	Lynn, Rachel C. "Targeting of folate receptor-beta on acute myeloid leukemia blasts with chimeric antigen receptor expressing T cells." Blood 125.22 (2015): 3466-3476.
description	4.	Rapoport, Aaron P. "NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma." Nature medicine 21.8 (2015): 914-21.
description	5.	Koneru, Renier J. "IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo." Oncoimmunology 4.3 (2015): 00-00.
description	6.	Rosenberg, Steven A. "A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response." Clinical cancer research 21.5 (2014): 1019-1027.
description	7.	Spear, P. "NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors." Immunology and cell biology 91.6 (2013): 435-440.

Select All Clear All Save Citations

Gene Therapy [0969-7128] Hombach, A yr:2001